Tyrosine kinase inhibitorPhase 3 trialInvestigational
Apatinib
How it works
Apatinib is a small molecule that blocks the VEGFR-2 receptor on cancer cells, reducing angiogenesis and tumor growth.
Cancer types
Efficacy
In clinical trials, apatinib improved overall survival in patients with pancreatic cancer, with a median survival of approximately 8.1 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.